| Oct 31 |
Teleflex Non-GAAP EPS of $3.49 beats by $0.10, revenue of $764.4M misses by $3.4M
|
| Oct 31 |
Teleflex Reports Third Quarter Financial Results and Full Year 2024 Outlook
|
| Oct 30 |
A Look Ahead: Teleflex's Earnings Forecast
|
| Oct 30 |
Teleflex Q3 2024 Earnings Preview
|
| Oct 29 |
Teleflex's (NYSE:TFX) Returns On Capital Not Reflecting Well On The Business
|
| Oct 29 |
First Patient Enrolled in Teleflex’s Barrigel™ Rectal Spacer Trial for Post Radical Prostatectomy Radiation Therapy (PPRT)
|
| Oct 28 |
Glaukos (GKOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
| Oct 28 |
TFX Stock to Gain From Launch of New Vascular Access Devices in Canada
|
| Oct 17 |
New Data Presented at ASTRO 2024 Further Demonstrate the Safety and Efficacy of Barrigel™ Rectal Spacer, the First and Only Sculptable Hyaluronic Acid Rectal Spacer, in Patients Undergoing Radiation Therapy for Prostate Cancer(1-3)
|
| Oct 17 |
Teleflex Announces Third Quarter 2024 Earnings Conference Call Information
|
